Journal Mobile Options
Table of Contents
Vol. 62, No. 3, 2004
Issue release date: September 2004
Horm Res 2004;62:137–141
(DOI:10.1159/000080064)

Hypoglycemia-Dependent β2-Adrenoceptor Downregulation: A Contributing Factor to Hypoglycemia Unawareness in Patients with Type-1 Diabetes?

Schwab K.O. · Menche U. · Schmeisl G. · Lohse M.J.
aDepartment of Pharmacology and Toxicology, University of Würzburg, bDepartment of Pediatrics, University of Freiburg, and cDiabetes-Reha-Klinik Fürstenhof, Bad Kissingen, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

To evaluate the influence of the incidence and unawareness of hypoglycemia on lymphocyte β2-adrenoceptor densities, we measured β2-adrenoceptor density using [125I]-iodocyanopindolol and CGP 12177 before and after 1 week of treatment optimization in 33 adults with type-1 diabetes mellitus. Diabetes treatment of all patients was modified to improve their glycemic control. During this week, all patients had to complete a protocol with 7 daily glucose measurements, one of which was at night. The subjective symptoms were evaluated in case of hypoglycemia. A significant correlation between a hypoglycemia incidence below (but not above) the threshold of 2.75 mmol/l (50 mg/dl) and β2-adrenoceptor densities on lymphocytes was found after the study week (r = –0.72, p < 0.00001). Nine patients suffering from hypoglycemia unawareness had a significantly higher incidence of hypoglycemia (p < 0.002) and lower β2-adrenoceptor densities on lymphocytes compared to 24 patients who recognized all of their hypoglycemic episodes (p < 0.004). We conclude that downregulation of β2-adrenoceptor densities on lymphocytes occurs as a result of recurrent hypoglycemia defined as glucose levels of <2.75 mmol/l. β2-Adrenoceptor densities are decreased in patients with subjective hypoglycemia unawareness and might contribute to the reduced β-adrenergic sensitivity in this subgroup of patients.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Cryer PE: Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM: A vicious cycle. Diabetes 1992;41:255–260.
  2. Cryer PE: Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol Endocrinol Metab 2001;281:E1115–E1121.
  3. Cryer PE: Hypoglycemia risk reduction in type 1 diabetes. Exp Clin Endocrinol Diabetes 2001;209(suppl 2):S412–S423.

    External Resources

  4. Cryer PE: Hypoglycaemia: The limiting factor in the glycaemic management of type 1 and type 2 diabetes. Diabetologia 2002;45:937–948.
  5. Segel SA, Fanelli CG, Dence CS, Markham J, Videen TO, Paramore DS, Powers WJ, Cryer PE: Blood-to-brain glucose transport, cerebral glucose metabolism and cerebral blood flow are not increased after hypoglycemia. Diabetes 2001;50:1911–1917.
  6. Hoffman RP, Singer-Granick C, Drash AL, Becker DJ: Abnormal alpha cell hypoglycemic recognition in children with insulin dependent diabetes mellitus. (IDDM). J Pediatr Endocrinol 1994;7:225–234.
  7. Liu D, Adamson UCK, Lins PES, Kollind ME, Moberg EAR, Andreasson K: Inhibitory effect of circulating insulin on glucagon secretion during hypoglycemia in type 1 diabetic patients. Diabetes Care 1992;15:59–65.
  8. Holl RW, Grabert M, Schwab KO, Zimmermann A, Heinze E: Factors related to the prevalence of nocturnal hypoglycemia in hospitalised children and adolescents with type 1 diabetes mellitus: Analysis in 2659 subjects from 62 centres. Diabetes 2001;50(suppl 2):A67 (272-OR).
  9. Boyle PJ: Alteration in brain glucose metabolism induced by hypoglycemia in man. Diabetologia 1997;40:S69–S74.
  10. Smith D, Amiel SA: Hypoglycemia unawareness and the brain. Diabetologia 2002;45:949–958.
  11. Berlin I, Grimaldi A, Bosquet F, Puech AJ: Decreased β-adrenergic sensitivity in insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1986;63:262–265.
  12. Fritsche A, Stumvoll M, Grub M, Sieslack S, Renn W, Schmulling RM, Haring HU, Gerich JE: Effect of hypoglycemia on beta-adrenergic sensitivity in normal and type 1 diabetic subjects. Diabetes Care 1998;21:1505–1510.
  13. Berlin I, Grimaldi A, Landault C, Zoghbi F, Thervet F, Puech AJ, Legrand JC: Lack of hypoglycemic symptoms and decreased β-adrenergic sensitivity in insulin-dependent diabetic patients. J Clin Endocrinol Metab 1988;66:273–278.
  14. Fritsche A, Stumvoll M, Haring HU, Gerich JE: Reversal of hypoglycemia unawareness in a long-term type 1 diabetic patient by improvement of beta-adrenergic sensitivity after prevention of hypoglycemia. J Clin Endocrinol Metab 2000;85:523–525.
  15. Korytkowski MT, Mokan M, Veneman TF, Mitrakou A, Cryer PE, Gerich JE: Reduced beta-adrenergic sensitivity in patients with type 1 diabetes and hypoglycemia unawareness. Diabetes Care 1998;21:1939–1943.
  16. Trovik TS, Jaeger R, Jorde R, Sager G: Reduced sensitivity to β-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness. Br J Clin Pharmacol 1994;38:427–432.
  17. Aarons RD, Nies AS, Gerber JG, Molinoff PB: Decreased β-adrenergic receptor density on human lymphocytes after chronic treatment with agonists. J Pharmacol Exp Ther 1983;224:1–6.
  18. Valet P, Damase-Michel C, Chamontin B; Durand D, Gaillard G, Salvador M, Montastruc JL: Adrenoceptors in the diagnosis of pheochromocytoma. Lancet 1987;ii:337.
  19. Sager G, Slordal L, Huseby NE, Florholmen J: β-Adrenoceptor regulation in insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 1991;51:283–288.
  20. Serusclat P, Rosen SG, Smith EB, Shah SD, Clutter WE, Cryer PE: Mononuclear leucocyte β2-adrenergic receptors and adenylate cyclase sensitivity in insulin-dependent diabetes mellitus. Diabetes 1983;32:825–829.
  21. Noji T, Tashiro M, Yagi H, Nagashima K, Suzuki S, Kuroume T: Adaptive regulation of β-adrenergic receptors in children with insulin dependent diabetes mellitus. Horm Metabol Res 1986;18:604–606.
  22. Schwab KO, Bartels H, Martin C, Leichtenschlag EM: Decreased granulocyte β2-adrenoceptor density and decreased lymphocyte cAMP increase in juvenile diabetes mellitus: An additional cause of severe hypoglycaemia in childhood diabetes ? Eur J Pediatr 1993;152:797–801.
  23. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR, Montoye HJ, Sallis JF, Paffenbarger RS: Compendium of physical activities: Classification of energy costs of human physical activities. Med Sci Sports Exerc 1993;25:71–80.
  24. Wilkinson GN: Statistical estimations in enzyme kinetics. Biochem J 1961;80:324–332.
  25. Danner S, Lohse MJ: Regulation of beta-adrenergic receptor responsiveness modulation of receptor gene expression, Review. Rev Physiol Biochem Pharmacol 1999;136:183–223.
  26. Brodde OE: Beta 1- and beta 2-adrenoceptors in the human heart: Properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991;43:203–242.
  27. Trovik TS, Jaeger R, Jorde R, Sager G: Reduced β-adrenergic sensitivity in healthy volonteers induced by hypoglycemia. Fundam Clin Pharmacol 1995;9:181–186.
  28. Ovalle F, Fanelli CG, Paramore DS, Hershey T, Craft S, Cryer PE: Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus. Diabetes 1998;47:1472–1479.
  29. Schwab KO, Leichtenschlag EM, Martin C, Bartels H: Symptoms of hypoglycaemia in children and adolescents with type 1 diabetes mellitus. Mschr Kinderheilkd 1997;145:120–127.

    External Resources

  30. Trovik TS, Vaartun A, Sager G: Altered cAMP response after isoprenalin stimulation of mononuclear leucocytes from insulin-dependent diabetic patients with hypoglycemia unawareness. Pharmacol Toxicol 1995;77:270–275.
  31. Trovik TS, Jaeger R, Jorde R, Sager G: Dysfunction in the β2-adrenergic signal pathway in patients with insulin dependent diabetes mellitus (IDDM) and unawareness of hypoglycaemia. Eur J Clin Pharmacol 1995;48:327–332.
  32. Fritsche A, Tschritter O, Häring H, Gerich J, Stumvoll M: The role of β-adrenergic sensitivity in the pathogenesis of hypoglyaemia unawareness. Diabetes Nutr Metab 2002;15:357–361.
  33. Fritsche A, Stefan N, Haring H, Gerich J, Stumvoll M: Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes. Ann Intern Med 2001;134:729–736.
  34. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA: Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994;344:283–288.
  35. Dagogo-Jack SE, Rattarasarn C, Cryer PE: Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994;43:1426–1434.
  36. Fanelli CG, Epifano L, Rambotti AM, Pampanelli S, Di Vincenzo A, Modarelli F, Lepore M, Annibale B, Ciofelta M, Bottini P, Porcellati F, Scionti L, Santeusanio F, Brunetti P, Bolli GB: Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993;42:1683–1689.
  37. Mitrakou A, Fanelli C, Veneman T, Periello G, Calderone S, Platanisiotis D, Rambotti A, Raptis S, Brunetti P, Cryer P, Gerich J, Bolli G: Reversibility of unawareness of hypoglycemia in patients with insulinomas. N Engl J Med 1993;329:834–839.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50